celecoxib has been researched along with Precursor Cell Lymphoblastic Leukemia-Lymphoma in 2 studies
Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with celecoxib also restored GSK3β function and led to down-regulation of β-catenin activity through transcriptional and post-translational mechanisms, two effects likely to contribute to Ph+ cell growth suppression by celecoxib." | 1.43 | Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2. ( Calabretta, B; Canonico, PL; Condorelli, F; De Dominici, M; Genazzani, AA; Gnemmi, I; Mariani, SA; Minassi, A; Minieri, V; Riva, B; Salomoni, P, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Riva, B | 1 |
| De Dominici, M | 1 |
| Gnemmi, I | 1 |
| Mariani, SA | 1 |
| Minassi, A | 1 |
| Minieri, V | 1 |
| Salomoni, P | 1 |
| Canonico, PL | 1 |
| Genazzani, AA | 1 |
| Calabretta, B | 1 |
| Condorelli, F | 1 |
| Johansson, AS | 1 |
| Pawelzik, SC | 1 |
| Larefalk, A | 1 |
| Jakobsson, PJ | 1 |
| Holmberg, D | 1 |
| Lindskog, M | 1 |
2 other studies available for celecoxib and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Lymphoblastic T-cell lymphoma in mice is unaffected by Celecoxib as single agent or in combination with cyclophosphamide.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothera | 2009 |